A bioequivalence study of two dipyridamole products.

Bioequivalence of Antiplate 75 mg was assessed versus Persantine 75 mg in a two-way crossover study. At the 5% confidence level, no significant difference was found between the area under the plasma concentration-time curves of the two products. The Cmax were comparable for both products. Quality control data including assay, content uniformity, disintegration and dissolution indicated that both products passed the pharmacopoeial requirements, USP XXI and BP 1980, Addendum 1983. It is concluded that Antiplate-75 is bioequivalent to Persantine.